Company Overview and News

2
Companhia Energetica (CIG) in Focus: Stock Moves 6.5% Higher

2018-10-04 zacks
Companhia Energetica de Minas Gerais (CIG - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.60 to $1.81 in the past one-month time frame.
ATP CSBR AT APRWF

12
Southern Company's Vogtle Project Survives Against All Odds

2018-09-27 zacks
The clouds of uncertainty looming over Southern Company’s (SO - Free Report) controversial Vogtle Plant has finally given way to sunshine. After prolonged delays and days of negotiation, all the four owners of the project have finally voted to proceed with the construction of the project. This marks a huge step toward strengthening America’s nuclear energy security. Notably, Georgia Power, a subsidiary of Southern Company, is the chief owner of the Vogtle project with 45.
SOJA GFN SO DUKH GFNCP GAPWP SCG AT DUK GPJA GFNSL GPEPRA AEE GPJ ATP SCU GFDV APRWF

 
BCE Unit Expands LTE Advanced Wireless Coverage in Manitoba

2018-09-25 zacks
Bell MTS, a wholly-owned subsidiary of BCE, Inc. (BCE - Free Report) , recently announced that it has extended LTE Advanced (LTE-A) wireless coverage network in Manitoba as part of its $1 billion infrastructure investment plan for the province. Notably, the expansion will bring the wireless service to the communities of Stuartburn, Woodridge and Zhoda.
AEE ATP AT PPL APRWF

2
TransCanada's Keystone XL Gets Nod From U.S. State Department

2018-09-25 zacks
Bringing in pleasant news for TransCanada Corporation (TRP - Free Report) , the U.S. State Department has finally green-lighted the company’s controversial Keystone XL project. Just a month back, a U.S. federal judge, Brian Morris, issued a decree requiring the State Department to conduct a fresh environmental evaluation of the Keystone XL pipeline under the new alternative route. The judge believed that the alternative route proposed by the Nebraska Public Utilities Commission had not been properly assessed.
TRP ATP AT TRP RGCO APRWF

12
Fate of Southern Co.'s Vogtle Rests Wholly on Oglethorpe

2018-09-25 zacks
In a recent development regarding Southern Company’s (SO - Free Report) controversial Vogtle Plant, Municipal Electric Authority of Georgia (MEAG), one of the important minority owners, has voted to proceed with the construction of the project. Georgia Power, a subsidiary of Southern Company, is the chief owner of the Vogtle project with 45.7% interest. Other co-owners include Oglethorpe Power, MEAG and Dalton Utilities, holding 30%, 22.
SOJA SO DUKH GAPWP SCG AT DUK GPJA GPEPRA GPJ ATP SCU APRWF

 
Why It's Worth Investing in TC PipeLines Stock Right Now

2018-09-21 zacks
We are upbeat about TC PipeLines, LP’s (TCP - Free Report) prospects and see it as a promising pick for now.
AT EOG TCP DNR ATP SHLX SRE SPG APRWF

12
Facebook Withdraws Direct Promotion of Political Campaigns

2018-09-21 zacks
Facebook (FB - Free Report) recently announced that the company will restrain from physically sending its employees to promote the use of the platform for political campaigns. Facebook had offered personalized services before the 2016 elections, detailing how candidates and political parties can use the social media platform to better reach voters. The company now intends to provide free and common information online globally to all the people and parties interested in creating awareness about their political campaigns.
FB AT EOG ATP GOOGL SRE TWTR VSH SPG APRWF

3
Allstate (ALL) Expects Catastrophe Loss of $186M in August

2018-09-21 zacks
Property and casualty insurer The Allstate Corporation (ALL - Free Report) expects to incur $186 million, pre-tax ($147 million after-tax) catastrophe loss for the month of August. These losses can be attributed to 16 events at an estimated cost of $137 million, pre-tax. The rest of the loss pertains to unfavorable reserve reestimates of prior-reported catastrophe losses.
AT HIG HGH 8685 GJT AVF AIG EOG ALL ATP SRE SPG APRWF

 
Progressive Corp. or Travelers Companies: Which Scores Higher?

2018-09-21 zacks
Property and casualty insurance industry has again endured the wrath of Mother Nature with the advent of hurricanes Florence and Lane. The third quarter of a year generally bears the brunt of unprecedented catastrophes as it marks the peak of hurricane season. Nonetheless, factors like better pricing, favorable rate environment, sturdy capital surplus, strengthening labor market and improving employment scenario poise the industry well for improved performances.
HALL TRV AT PGR EOG ATP SRE SPG Y APRWF

4
FDA Confirms Positive Safety Profile of Acadia's Nuplazid

2018-09-21 zacks
Shares of ACADIA Pharmaceuticals Inc. (ACAD - Free Report) soared 26.6% after the FDAissued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis. However, shares of the company have decreased 36.5% year to date compared with the industry’s decline of 3.5%.
REGN GILD AT LGNDZ EOG ACAD ATP SRE LGNZZ LGND LGNYZ LGNXZ SPG APRWF

1
Disney Reportedly Working with Marvel Studios on Short Series

2018-09-21 zacks
Disney (DIS - Free Report) , according to reports, is working with its subsidiary, Marvel Studios, on a short series for its streaming service, per Variety. The service, set to launch in late 2019, will comprise a limited series based on popular characters from Marvel Cinematic Universe (MCU). The series will be produced by Marvel Studios and Kevin Feige, a key person with the studios, is expected to be part of the development.
ATP SRE AAPL AT NFLX SPG APRWF EOG

4
Philips Evolves as a Healthcare Company, Tariffs a Concern

2018-09-21 zacks
On Sep 21, we issued an updated research report on Koninklijke Philips N.V. (PHG - Free Report) . The company reports operations primarily under three segments - Personal Health businesses (accounted for 41.1% of total sales in 2017), Diagnosis & Treatment businesses (38.8%), and Connected Care & Health Informatics businesses (17.8%). The company also identifies HealthTech Other and Legacy Items. Philips is gradually evolving as a healthcare company, having augmented its presence in the domain, primarily driven by an expanding portfolio.
AT PAYC EOG ATP SRE VSH SPG NTAP PHG APRWF

12
Amazon Roundup: Ad Market Share, Store Expansion, Prime, More

2018-09-21 zacks
Amazon (AMZN - Free Report) may be rapidly gaining digital advertising market share, but it also has a comprehensive physical store expansion up its sleeve. So despite the valuation, analysts continue to raise their price targets-
WFCNP FB AT WMT LNSTY WFC EOG ATP GOOGL SRE MSFT SPG APRWF

 
Atlantic Power to Acquire Biomass Plants From EDF Renewables

2018-09-21 zacks
Atlantic Power Corporation (AT - Free Report) recently announced that it has entered into an agreement with EDF Renewables Inc. to acquire two biomass plants in South Carolina for $13 million. The two plants are the Allendale plant and the Dorchester plant, located in Allendale and Harleyville, South Carolina, respectively. The plants have a total capacity of 20 megawatts (MW) each. The company expects to close the deal in the second half of 2019 and the acquisition will be funded by the company’s discretionary cash.
AEE CMSA ATP NYLD AT CMS UTX NYLD.A APRWF EOG

12
Southern Co.'s Vogtle in Doldrums, Decision Due on Sep 30

2018-08-24 zacks
The dark cloud of uncertainty hovering over The Southern Company’s (SO - Free Report) Vogtle project does not seem to dissolve. Even after the approval of the project by Georgia Public Service Commission (PSC) in December 2017, the power plant has again been hit by a fresh controversy, which can even result in the scrapping of the project. Presently, the fate of the Vogtle Projects rests on the minority holders.
SOJA SO DUKH GAPWP SCG AT DUK GPJA GPEPRA GPJ ATP SCU APRWF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...